15 Jun 2015 07:00
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Appointment of Chief Financial Officer
On 12 May 2015, Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announced the appointment of Jonathan Hartshorn as Chief Financial Officer with effect from 15th June 2015.
The Company is pleased to confirm that Jonathan will begin his duties in that role today.
The Company reaffirms that save as disclosed in the announcement of 12 May 2015, there are no other disclosures required in relation to paragraph (g) of Schedule 2 of the AIM Rules for Companies.
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Orla Mc Guinness, Marketing Manager
| Tel: +33 676 93 11 78 |
Zeus Capital (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones | Tel: 0161 831 1512 |
Alex Davies | Tel: 020 7533 7727 |
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or venn@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Lianne Cawthorne | Mob: +44 (0)7584 391 303 |
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.